Barnes Aktie - B

Echtzeit-Diskussionen und Handelsideen: Handeln Sie mit Zuversicht mit unserer leistungsstarken Plattform.

Premium

Current Price

47,48

Gebot

Fragen

Volumen

0,00 Tagesbereich 0,00

32,65 52-Wochen-Bereich 47,50

Handelsende

47,48

Handelsbeginn

Letzte Trade

Letzter Handelszeitpunkt

Durchschnittliches Volumen (3 Mio.)

210.767

Finanzvolumen

VWAP

Sweco publishes Annual and Sustainability Report for 2024

Sweco publishes Annual and Sustainability Report for 2024 PR Newswire STOCKHOLM, March 31, 2025 STOCKHOLM, March 31, 2025 /PRNewswire/ -- Sweco...

Integrum implements new compensation package for its CEO

Integrum implements new compensation package for its CEO PR Newswire MÖLNDAL, Sweden, March 28, 2025 MÖLNDAL, Sweden , March 28, 2025...

BioArctic's partner Eisai presents sales simulation for Leqembi® at its annual press conference

BioArctic's partner Eisai presents sales simulation for Leqembi® at its annual press conference PR Newswire STOCKHOLM, March 25, 2025 STOCKHOLM...

BioArctic receives Orphan Drug Designation for exidavnemab the US

BioArctic receives Orphan Drug Designation for exidavnemab the US PR Newswire STOCKHOLM, March 17, 2025 STOCKHOLM, March 17, 2025 /PRNewswire/...

Therapeutic Goods Administration decides not to register lecanemab in Australia

Therapeutic Goods Administration decides not to register lecanemab in Australia PR Newswire STOCKHOLM, Sweden, March 3, 2025 STOCKHOLM, Sweden...

Therapeutic Goods Administration decides not to register lecanemab in Australia

Therapeutic Goods Administration decides not to register lecanemab in Australia PR Newswire STOCKHOLM, Sweden, March 3, 2025 STOCKHOLM, Sweden...

Large Swedish healthcare region expands use of Sectra's solution with digital pathology to enhance cancer diagnostics

Large Swedish healthcare region expands use of Sectra's solution with digital pathology to enhance cancer diagnostics PR Newswire LINKÖPING...

Form 15-12G - Securities registration termination [Section 12(g)]

Form 4 - Statement of changes in beneficial ownership of securities

Zeitraum †	Änderung	Änderung %	Handelsbeginn	Hoch	Niedrig	Durchsch. Volumen	VWAP
1	0	0	47.48	47.48	47.48	0	0	CS
4	0	0	47.48	47.48	47.48	0	0	CS
12	0.235	0.49740713303	47.245	47.5	47.23	210767	47.3657329	CS
26	8.99	23.3567160301	38.49	47.5	38.34	533150	46.75768771	CS
52	11.77	32.9599551946	35.71	47.5	32.65	420327	43.81806285	CS
156	7.22	17.9334326875	40.26	47.5	18.79	316939	38.48151344	CS
260	10.71	29.1270057112	36.77	57.64	18.79	273141	40.3276919	CS

B - Frequently Asked Questions (FAQ)

What is the current Barnes share price?

The current share price of Barnes is US$ 47,48

What is the 1 year trading range for Barnes share price?

Barnes has traded in the range of US$ 32,65 to US$ 47,50 during the past year

Volumen
% Tops
% Flops

Symbol	Preis	Vol.
AAMAA Mission Acquisition Corp	US$ 10,27 (0,00%)	0
AACT.UAres Acquisition Corporation II	US$ 11,43 (0,00%)	0
AACTAres Acquisition Corporation II	US$ 11,14 (0,00%)	0
AAAlcoa Corporation	US$ 30,14 (0,00%)	0
AAgilent Technologies	US$ 114,05 (0,00%)	0
AAMAA Mission Acquisition Corp	US$ 10,27 (0,00%)	0
AACT.UAres Acquisition Corporation II	US$ 11,43 (0,00%)	0
AACTAres Acquisition Corporation II	US$ 11,14 (0,00%)	0
AAAlcoa Corporation	US$ 30,14 (0,00%)	0
AAgilent Technologies	US$ 114,05 (0,00%)	0
AAMAA Mission Acquisition Corp	US$ 10,27 (0,00%)	0
AACT.UAres Acquisition Corporation II	US$ 11,43 (0,00%)	0
AACTAres Acquisition Corporation II	US$ 11,14 (0,00%)	0
AAAlcoa Corporation	US$ 30,14 (0,00%)	0
AAgilent Technologies	US$ 114,05 (0,00%)	0

Foren

Foren anzeigen

Keine Diskussionen Gefunden.

Neuen Thread Erstellen

Marktdaten

News

Werkzeuge

Märkte

Entdecken

Hot Features

Follow Feed

Optionen-Flow

Watchlist

Barnes Group Inc (B)

Echtzeit-Diskussionen und Handelsideen: Handeln Sie mit Zuversicht mit unserer leistungsstarken Plattform.

Wichtige Statistiken und Details

B Neueste Nachrichten

Sweco publishes Annual and Sustainability Report for 2024

Integrum implements new compensation package for its CEO

BioArctic's partner Eisai presents sales simulation for Leqembi® at its annual press conference

BioArctic receives Orphan Drug Designation for exidavnemab the US

Therapeutic Goods Administration decides not to register lecanemab in Australia

Therapeutic Goods Administration decides not to register lecanemab in Australia

Large Swedish healthcare region expands use of Sectra's solution with digital pathology to enhance cancer diagnostics

Form 15-12G - Securities registration termination [Section 12(g)]

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Sweco publishes Annual and Sustainability Report for 2024

Integrum implements new compensation package for its CEO

BioArctic's partner Eisai presents sales simulation for Leqembi® at its annual press conference

BioArctic receives Orphan Drug Designation for exidavnemab the US

Therapeutic Goods Administration decides not to register lecanemab in Australia

Therapeutic Goods Administration decides not to register lecanemab in Australia

Large Swedish healthcare region expands use of Sectra's solution with digital pathology to enhance cancer diagnostics

Form 15-12G - Securities registration termination [Section 12(g)]

B - Frequently Asked Questions (FAQ)

Beweger

Foren

Kürzlich von Ihnen besucht

Unternehmen

Geschäft

Popular

App herunterladen

Trends

Toplisten

Marktdaten

News

Werkzeuge

Märkte

Entdecken

Hot Features

Follow Feed

Optionen-Flow

Watchlist

Barnes Group Inc (B) Börsenkurse

Barnes Group Inc (B)

Echtzeit-Diskussionen und Handelsideen: Handeln Sie mit Zuversicht mit unserer leistungsstarken Plattform.

Wichtige Statistiken und Details

B Neueste Nachrichten

Sweco publishes Annual and Sustainability Report for 2024

Integrum implements new compensation package for its CEO

BioArctic's partner Eisai presents sales simulation for Leqembi® at its annual press conference

BioArctic receives Orphan Drug Designation for exidavnemab the US

Therapeutic Goods Administration decides not to register lecanemab in Australia

Therapeutic Goods Administration decides not to register lecanemab in Australia

Large Swedish healthcare region expands use of Sectra's solution with digital pathology to enhance cancer diagnostics

Form 15-12G - Securities registration termination [Section 12(g)]

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Sweco publishes Annual and Sustainability Report for 2024

Integrum implements new compensation package for its CEO

BioArctic's partner Eisai presents sales simulation for Leqembi® at its annual press conference

BioArctic receives Orphan Drug Designation for exidavnemab the US

Therapeutic Goods Administration decides not to register lecanemab in Australia

Therapeutic Goods Administration decides not to register lecanemab in Australia

Large Swedish healthcare region expands use of Sectra's solution with digital pathology to enhance cancer diagnostics

Form 15-12G - Securities registration termination [Section 12(g)]

B - Frequently Asked Questions (FAQ)

Beweger

Foren

Kürzlich von Ihnen besucht

Unternehmen

Geschäft

Popular

App herunterladen

Werbung entfernen